Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470484 | 0.85 | PRMT5 (0.60) | PRMT5KDM4ETLR8POLBCYP1A2 | |
| SCHEMBL5088695 | 0.78 | TLR8 (0.55) | PRMT5TLR8POLB | |
| SCHEMBL5457312 | 0.75 | PRMT5 (0.66) | PRMT5KDM4ETLR8POLBCYP1A2 | |
| SCHEMBL5448072 | 0.74 | PRMT5 (0.64) | PRMT5KDM4ETLR8POLBCYP1A2 | |
| SCHEMBL5104145 | 0.74 | PRMT5 (1.00) | PRMT5KDM4ETLR8POLBHTT | |
| SCHEMBL5454914 | 0.72 | PRMT5 (0.57) | PRMT5KDM4ETLR8POLBCYP1A2 | |
| SCHEMBL5455913 | 0.71 | PRMT5 (0.60) | PRMT5KDM4ETLR8POLBCYP1A2 | |
| SCHEMBL5459067 | 0.71 | PRMT5 (0.60) | PRMT5KDM4ETLR8POLBHTT | |
| SCHEMBL5452004 | 0.71 | PRMT5 (0.55) | PRMT5KDM4ETLR8POLBCYP1A2 | |
| SCHEMBL5141325 | 0.70 | PRMT5 (0.58) | PRMT5KDM4ETLR8POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101405000-A | 2-imino-benzimidazoles | ABBOTT LAB (US) | 2009-04-08 | — | — | CN | disclosed |
| EP-1983992-A2 | 2-IMINO-BENZIMIDAZOLES | Abbott Laboratories (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| WO-2007084728-A2 | 2-IMINO-BENZIMIDAZOLES | ABBOTT LABORATORIES (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | PRMT5 2145/4885KDM4E 2704/4885TLR8 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.